I am pleased that Jung and colleagues (Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010;62:863–8) were able to independently confirm findings from our 23-year-old study of 92 patients with systemic lupus erythematosus (SLE), in which we showed that hydroxychloroquine was statistically significantly protective against thrombovascular events (Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? [letter]. Arthritis Rheum 1987;30:1435–6). Their statement that the issue had only been addressed in non-SLE populations was in error.
Thrombovascular Events in Systemic Lupus Erythematosus: Comment on the Article by Jung et al
To the Editor:
Daniel J. Wallace MD*, * Cedars-Sinai Medical Center, University of California, Los Angeles.